Back to Sites

St. Jude Children's Research Hospital CRS

Site Number

6501

Address

St. Jude Children's Research Hospital
262 Danny Thomas Place
Patient Care Center, 3rd Floor
Memphis, TN 38105
United States of America

IMPAACT Members at this Site

Debra Livingston CAB Liaison

Ronald Dallas Clinical Research Assistant

Robbin Christensen Co-Investigator

Judy Glenn Co-Investigator

Jennifer Griffith Co-Investigator

Nanna Howlett Co-Investigator

Susannah Keck Co-Investigator

Lennie Lott Co-Investigator

Donna Nance Co-Investigator

Nina Sublette Co-Investigator

Jamie Russell CRS Coordinator

Jill Utech CRS Coordinator

Patricia Flynn CRS Leader

Aditya Gaur CRS Leader

Marion Donohoe CRS Staff

Julie Maier CRS Staff

Christine Sinnock CRS Staff

Megan Loughran CTU Coordinator

Stephen Spector CTU Principal Investigator

Blanca Castillo DAIDS PO

Patricia Flynn Investigator

Aditya Gaur Investigator

Nehali Patel Investigator

Nina Sublette Investigator

Edwin Thorpe Jr. Investigator

Sherri Flax Local Laboratory

Terrence Geiger Local Laboratory

Susan Carr Pharmacist of Record

Katherine Knapp Principal Investigator

Studies at this Site

P1080: ARV & Psychiatric Medication Concentrations in HIV Infected & Uninfected Children

DAIDS Number

10768

Research Area

Brain and Mental Health

Study Status

Concluded

P1097: Raltegravir PK Study

DAIDS Number

11790

Research Area

Treatment

Study Status

Concluded

P1110: Safety and PK of RAL in Neonates

DAIDS Number

11891

Research Area

Treatment

Study Status

Concluded

P1115: Very Early Intensive Treatment of Infants Living with HIV to Achieve HIV Remission: A Phase I/II Proof of Concept Study

DAIDS Number

11954

Research Area

Cure and Immunotherapy

Study Status

Enrolling

IMPAACT 2000: A Phase I Study of the Safety and Immunogenicity of Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine RSV LID delta M2-2 in RSV-Seronegative Infants and Children

DAIDS Number

12016

Research Area

Complications & Comorbidities

Study Status

Concluded

IMPAACT 2002: Combined Cognitive Behavioral Therapy and a Medication Management Algorithm for Treatment of Depression among Youth Living with HIV in the United States

DAIDS Number

12051

Research Area

Brain and Mental Health

Study Status

Participants Off Study and Primary Analysis Completed

IMPAACT 2007: Phase I Safety and Pharmacokinetic Study of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection

DAIDS Number

20734

Research Area

Treatment

Study Status

Concluded

IMPAACT 2011: Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID delta M2-2 1030s, Lot RSV#010A, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age

DAIDS Number

30072

Research Area

Complications & Comorbidities

Study Status

Concluded

IMPAACT 2012: Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID cp delta M2-2, Lot RSV#009B, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age

DAIDS Number

30073

Research Area

Complications & Comorbidities

Study Status

Concluded

IMPAACT 2013: Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, D46/NS2/N/delta M2-2-HindIII, Lot RSV#011B, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age

DAIDS Number

30074

Research Area

Complications & Comorbidities

Study Status

Concluded